Adult CIRB - Early Phase Emphasis Meeting Agenda
February 15, 2022

I Continuing Review

10218, A Phase 1b Trial of Telaglenastat (CB-839) HCl in Combination with Radiation Therapy and Temozolomide in Patients with IDH-mutated Diffuse Astrocytoma and Anaplastic Astrocytoma (Protocol Version Date 10/12/21)

II Continuing Review

10222, A Phase II study of olaparib and AZD6738 in isocitrate dehydrogenase (IDH) mutant solid tumors (Protocol Version Date 09/14/21)

III Continuing Review

10240, Phase II Study of XL184 (cabozantinib) in combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-refractory Differentiated Thyroid Cancer whose Cancer Progressed after One Prior VEGFR-Targeted Therapy (Protocol Version Date 01/28/21)

IV Continuing Review

10330, A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma (Protocol Version Date 06/15/21)

V Continuing Review

ABTC-1701, Pilot Surgical PK Study of Bemcentinib in Recurrent Glioblastoma Patients (Protocol Version Date 10/07/21)

VI New Study - Initial Review

10504, A Randomized Phase 2 Study of Atezolizumab with or without Selinexor in Alveolar Soft Part Sarcoma (AXIOM) (Protocol Version Date 12/17/21)
VII  New Study - Initial Review

10512, A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer (Protocol Version Date 01/12/22)

VIII  Amendment

10292, DURVA+: Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination with Chemotherapy in Patients with Advanced Solid Tumors (Protocol Version Date 01/13/22)

IX  Amendment

10410, A Phase 1 Study of IPdR in Combination with Capecitabine and Radiotherapy in Rectal Cancer (Protocol Version Date 01/07/22)